Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Wakula, P; Bisping, E; Kockskamper, J; Post, H; Brauer, S; Deuter, M; Oehlmann, R; Besenfelder, U; Lai, FA; Brem, G; Pieske, B.
CMV promoter is inadequate for expression of mutant human RyR2 in transgenic rabbits
J Pharmacol Toxicol Methods. 2010; 63(2):180-185 Doi: 10.1016/j.vascn.2010.09.007
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Pieske Burkert Mathias
Wakula-Heinzel Paulina
Co-Autor*innen der Med Uni Graz
Bisping Egbert Hubertus
Kockskämper Jens
Post Heiner
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Introduction: Fundamental differences in Ca(2+) homeostasis between mice and larger mammals require the validation of the mechanisms of arrhythmogenesis before translation into human pathophysiology. The purpose of this study was to create transgenic rabbits that express defective human cardiac ryanodine receptor (hRyR2) with a mutation (R4497C) causing a clinically relevant arrhythmogenic syndrome. Methods: The construct pcDNA3-EGFP-hRyR2-R4497C with the CMV promoter was used to generate transgenic rabbits. The founder animals were created by microinjection and identified by PCR with specific primers for the EGFP sequence. The copy number of the transgene was quantified by real-time PCR using genomic DNA from blood cells. mRNA expression of EGFP-hRyR2-R4497C was quantified using RT-PCR with specific primers for the RyR2 and EGFP sequence. Protein expression of the transgene in heart and non-cardiac tissues was determined using immunoblots with antibodies directed against EGFP and RyR2. Results: Real-time PCR in peripheral blood cells identified several rabbit lines with the construct integrated into their genome. Transcription levels of the transgene were low (Ct > 30). On the protein level, neither EGFP nor hRyR2 R4497C was detected in either cardiac or non-cardiac tissue. A truncated gene product (3' end and central part of hRyR2 R4497C, but not EGFP) could be detected at the mRNA level in the heart. Discussion: Lack of significant protein expression of the EGFP-RyR2 R4497C gene construct despite successful incorporation into the genomic DNA is due to combination of at least two factors: low mRNA expression, and truncation of the transgene on the mRNA level. Our results suggest that the CMV promoter may not be well suited for creating transgenic rabbits. (C) 2010 Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Animals -
Animals, Genetically Modified - genetics
Cytomegalovirus - genetics
Gene Expression -
Green Fluorescent Proteins - biosynthesis Green Fluorescent Proteins - chemistry Green Fluorescent Proteins - genetics
Humans -
Mice -
Mutation -
Myocardium - metabolism
Promoter Regions, Genetic -
RNA, Messenger - biosynthesis RNA, Messenger - genetics
Rabbits - blood Rabbits - genetics
Recombinant Fusion Proteins - biosynthesis Recombinant Fusion Proteins - chemistry Recombinant Fusion Proteins - genetics
Reverse Transcriptase Polymerase Chain Reaction - methods
Ryanodine Receptor Calcium Release Channel - biosynthesis Ryanodine Receptor Calcium Release Channel - genetics
Tachycardia, Ventricular - genetics Tachycardia, Ventricular - metabolism
Transgenes -

Find related publications in this database (Keywords)
CMV promoter
Ryanodine receptor 2 (RyR2)
Transgenic rabbits
Methods
© Med Uni Graz Impressum